A multilaboratory, multicountry study to determine MIC quality control ranges for phenotypic drug susceptibility testing of selected first-line antituberculosis dugs, second-line injectables, fluoroquinolones, clofazimine, and linezolid

Show simple item record

dc.contributor.author Kaniga, Koné
dc.contributor.author Cirillo, Daniela M.
dc.contributor.author Hoffner, Sven
dc.contributor.author Ismail, Nazir Ahmed
dc.contributor.author Kaur, Devinder
dc.contributor.author Lounis, Nacer
dc.contributor.author Metchock, Beverly
dc.contributor.author Pfyffer, Gaby E.
dc.contributor.author Venter, Amour
dc.date.accessioned 2017-04-07T06:49:38Z
dc.date.issued 2016-12
dc.description.abstract OBJECTIVES : Our objective was to establish reference minimal inhibitory concentration (MIC) quality control (QC) ranges for drug susceptibility testing of antimycobacterials, including firstline agents, second-line injectables, fluoroquinolones and World Health Organization Category 5 drugs for multidrug-resistant tuberculosis, using a 7H9 broth microdilution MIC method. METHODS : A Tier-2 reproducibility study was conducted in eight participating laboratories using Clinical Laboratory and Standards Institute (CLSI) guidelines. Three lots of custom-made frozen 96-well polystyrene micro titer plates were used and pre-prepared with 2X pre-diluted drugs in 7H9 broth/oleic acid albumin dextrose catalase. The QC reference strain was Mycobacterium tuberculosis (MTB) H37Rv. MIC frequency, mode and geometric mean were calculated for each drug. QC ranges were derived, based on predefined, strict CLSI criteria. Any data lying outside CLSI criteria resulted in exclusion of the entire laboratory dataset. RESULTS : Data from one laboratory were excluded due to higher MIC values than for other laboratories. QC ranges were established for eleven drugs: isoniazid (0.03–0.12 μg/ml), rifampin (0.03–0.25 μg/ml), ethambutol (0.25–2 μg/ml), levofloxacin (0.12–1 μg/ml), moxifloxacin (0.06–0.5 μg/ml), ofloxacin (0.25–2 μg/ml), amikacin (0.25–2 μg/ml), kanamycin (0.25–2 μg/ml), capreomycin (0.5–4 μg/ml), linezolid (0.25–2 μg/ml) and clofazimine (0.03–0.25 μg/ml). QC ranges could not be established for nicotinamide (pyrazinamide surrogate), prothionamide or ethionamide, which were assay non-performers. CONCLUSIONS : Using strict CLSI criteria, QC ranges against the MTB H37Rv reference strain were established for the majority of commonly used antituberculosis drugs, with a convenient 7H9 broth microdilution MIC method suitable for use in resource-limited settings. en_ZA
dc.description.department Medical Microbiology en_ZA
dc.description.embargo 2017-06-30
dc.description.librarian hb2017 en_ZA
dc.description.sponsorship All participating laboratories received funds for this study from Janssen Pharmaceuticals except the Reference Laboratory, Division of TB Elimination, United States Centers for Disease Control and Prevention, Atlanta, GA, USA. Support for medical writing assistance was provided by Janssen Pharmaceuticals. en_ZA
dc.description.uri http://jcm.asm.org en_ZA
dc.identifier.citation Kaniga, K, Cirillo, DM, Hoffner, S, Ismail, NA, Kaur, D, Lounis, N, Metchock, B, Pfyffer, GE & Venter, A 2016, 'A multilaboratory, multicountry study to determine MIC quality control ranges for phenotypic drug susceptibility testing of selected first-line antituberculosis dugs, second-line injectables, fluoroquinolones, clofazimine, and linezolid', Journal of Clinical Microbiology, vol. 54, no. 12, pp. 2963-2968. en_ZA
dc.identifier.issn 0095-1137 (print)
dc.identifier.issn 1098-660X (online)
dc.identifier.other 10.1128/JCM.01138-16
dc.identifier.uri http://hdl.handle.net/2263/59700
dc.language.iso en en_ZA
dc.publisher American Society for Microbiology en_ZA
dc.rights © 2016, American Society for Microbiology. All Rights Reserved. en_ZA
dc.subject Validation en_ZA
dc.subject Antimycobacterials en_ZA
dc.subject Minimal inhibitory concentration (MIC) en_ZA
dc.subject Quality control (QC) en_ZA
dc.subject Mycobacterium tuberculosis (MTB) en_ZA
dc.title A multilaboratory, multicountry study to determine MIC quality control ranges for phenotypic drug susceptibility testing of selected first-line antituberculosis dugs, second-line injectables, fluoroquinolones, clofazimine, and linezolid en_ZA
dc.type Postprint Article en_ZA


Files in this item

This item appears in the following Collection(s)

Show simple item record